The landscape of photoaging: From bench to bedside in a bibliometric analysis.

Background: Bibliometric software exists as a platform providing multiple algorithms to process the data to suffice diverse goals. Interpretation of the result must be based on insight into the meaning of the original data and the algorithm used. Medical Subject Headings (MeSH) terms represent the macro-level meaning of topics, keywords that commonly reflect the micro-level aspects. Objective: This study attempts to investigate the landscape of photoaging in the recent two decades by using bibliometric analysis. Methods: Published studies of photoaging were obtained from PubMed and Web of Science Core Collection (WoSCC) from 2000 to 2020. Basic bibliometric information was generated by WoSCC. Major MeSH terms were performed in cluster analysis and displayed as a hierarchical form to induce knowledge structure, detection algorithm on keywords was presented as a timeline form to obtain hotspots, and institutional clusters were labeled with keywords to achieve institutional characteristics. Results: A total of 2,727 and 2,705 studies were identified in PubMed and WoSCC, respectively. The number of photoaging-related studies at 3-year intervals grew steadily. The studies were performed in about 80 countries/regions. The highly frequent major MeSH terms were distributed in seven clusters, reflecting the etiology, pathophysiology, treatment, and prevention of photoaging. The hotspots changed as time went on, and the hotspots in recent 5 years were mitogen-activated protein kinase (MAPK), nuclear factor erythroid-derived 2-like 2 (Nrf2), and antioxidant activity. The highly productive institutions labeling in the top four clusters were Seoul National University, University of Michigan, China Medical University, and Harvard University, with corresponding keywords of UVB, retinoic acid, Nrf2, and rejuvenation. Conclusions: This study built a knowledge structure of pathophysiology, treatment and prevention of photoaging, and identified recent hotspots of MAPK, Nrf2, and antioxidant activity. We provide a landscape of photoaging, from the bench (pathophysiology) to bedside (treatment, prevention), and pave the way for future research.

Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers.

AIM: To investigate the safety, tolerability and pharmacokinetics of intravenous hemoporfin, a novel photosensitive drug for the treatment of port-wine stain (PWS), in healthy Chinese volunteers following single-dose administration. METHODS: Thirty-six healthy Chinese subjects were enrolled. The subjects were administered hemoporfin (2.5, 5, 7.5 or 10 mg/kg) via single-dose intravenous infusion. Pharmacokinetics of the drug were studied in the groups with doses of 2.5, 5 and 7.5 mg/kg, and tolerability was studied in all the 4 groups. Safety and tolerance were evaluated by monitoring adverse events and laboratory parameters, and pharmacokinetics were assessed by determining hemoporfin content with a validated high-performance liquid chromatography with fluorescence detection (HPLC/FLD) method. RESULTS: Mild and transient adverse events occurred in the trial (n=10), but none were serious, and no subjects were withdrawn from the trial. The gastrointestinal tract adverse events, such as nausea, stomach upset, abdominal pain and vomiting, were observed in the groups with doses of 7.5 and 10 mg/kg. Increased alanine aminotransferase (ALT) concentration was found in 3 subjects, and increased alkaline phosphatase (ALP) concentration in one subject. The half-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively. C(max) and AUC increased with dose for intravenous single-dose administration of hemoporfin in the 2.5, 5, and 7.5 mg/kg groups. Urinary excretion of hemoporfin within 12 h was less than 0.2%. CONCLUSION: Hemoporfin is safe and well-tolerated in healthy Chinese volunteers at a single intravenous dose of up to 10 mg/kg. It was rapidly cleared from the blood and had a short half-life, which insures a short light-avoidance period.

Safety and pharmacokinetic studies of silodosin, a new α1A-adrenoceptor selective antagonist, in healthy Chinese male subjects.

The objectives of the study were to assess the safety and pharmacokinetics of silodosin capsules in 82 healthy male Chinese subjects. To evaluate the safety after single-dosing escalation, 40 subjects were equally divided into 4 groups (2, 4, 8, 12 mg) by a randomized, double-blind and placebo-controlled design. To assess the pharmacokinetics after single-dosing, 30 subjects were equally divided into 3 groups (4, 8, 12 mg). To assess the safety and pharmacokinetics via multiple-dosing, 12 subjects were included as a group (4 mg once daily at day 1 and day 7; 4 mg twice daily at day 2 through day 6). The safety observations showed that mild adverse events, including postural hypotension, dizziness, and headache, were observed. After single-dosing at doses of 4, 8, and 12 mg, the mean area under the concentration-time curve from 0 to 36 h (AUC(0-36)) values were 136.82±46.38, 270.17±54.66, and 474.63±108.50 µg/l·h and the mean maximal silodosin concentration in plasma (C(max)) values were 26.70±7.48, 48.47±12.35, and 94.07±22.59 µg/l, respectively. After multiple-dosing, the C(max) value at day 7 was 33.84±19.54 µg/l, and the AUC(0-24) value at day 7 was 193.19±68.96 µg/l·h. The accumulation ratio of the AUC value was 1.55 by comparing the multiple-dosing with the single-dosing. It is concluded that silodosin is safe and tolerated in healthy Chinese male subjects at the dosing levels used in this study. The mean C(max) and AUC values of silodosin increased proportionally with dose escalation, showing characteristics of linear pharmacokinetics.

An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum.

BACKGROUND: People have more and more concerned about allitridum as studies have shown that taking more raw garlic associated with a lower risk for cancers of the alimentary system. In the present study, we tried to examine whether a large dose of allitridum and a microdose of selenium prevent gastric cancer. METHODS: A double-blind intervention study was performed on the participants aged (35 - 74) years, who had matched at least one of the following criteria: (1) a medical history of stomach disorder, (2) a family history of tumour, or (3) smoking and/or alcohol consumption. A total of 2,526 and 2,507 persons were randomly enrolled into intervention group and control group respectively from 288 natural villages of seven communities in Qixia County, Shandong Province, China. Each person of the intervention group orally took 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month of each year during November 1989 to December 1991. At the same time, people in control group were given 2 placebo capsules containing corn oid with the identical appearance to that in the intervention group. RESULTS: For all subjects the large dose of allitridum was accepted and no harmful side effects were found during the study. In the first follow-up five years (1992 - 1997) after stopping the intervention, the morbidity rates of malignant tumours in the intervention group declined by 22%, in contrast to the control group, declined by 47.3%. After adjusting for age, gender, and other potential confounders, relative risks (RRs) for all tumours and gastric cancer of the whole population were 0.67 (95% CL: 0.43 - 1.03) and 0.48 (95% CL: 0.21 - 1.06), respectively, and for male group they were 0.51 (95% CL: 0.30 - 0.85) and 0.36 (95% CL: 0.14 - 0.92), respectively. No signigicantly protective effect was found for the female subgroup. CONCLUSION: The present study proves that large doses of allitridum and microdorse of selenium may effectively prevent gastric cancer, especially in men.